Chemotherapy News and Research

Latest Chemotherapy News and Research

New DNA-based test could better predict treatment outcomes for prostate cancer patients

Researchers at The Ontario Institute for Cancer Research and University Health Network, have identified a new DNA-based test that could be used to better predict how prostate cancer patients will respond to treatment and to prevent relapse.

13 Nov 2014

High-absorption BCM-95 Curcumin can reduce spread of cancer cells

A recently published cellular study on colorectal cancer showed that high-absorption BCM-95 Curcumin is able to reduce the spread of cancer cells and potentially increase the effectiveness of chemotherapy in the treatment of advanced colon cancer.

11 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Prof. Dan Peer awarded grant for groundbreaking development in cancer treatment

Prof. Dan Peer of Tel Aviv University's Department of Cell Research and Immunology will be awarded $10,000 for his groundbreaking development in cancer treatment at the inaugural Untold News Awards on Wednesday, November 12, 2014, from 6:00 to 8:00 p.m. at the Harmonie Club in New York City.

9 Nov 2014

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).

7 Nov 2014

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin (trade name: Halaven) is approved for women with locally advanced or metastatic breast cancer in whom the disease has progressed despite prior drug therapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups.

7 Nov 2014

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's today announced the opening of patient enrollment for its new cellular immunotherapy clinical research trial designed to induce remission in children suffering from neuroblastoma, one of the deadliest forms of childhood cancer.

7 Nov 2014

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.

7 Nov 2014

Researchers develop 'smart bomb' to attack B-lineage ALL

Fatih Uckun, Jianjun Cheng and their colleagues have taken the first steps towards developing a so-called "smart bomb" to attack the most common and deadly form of childhood cancer — called B-lineage acute lymphoblastic leukemia (ALL).

6 Nov 2014

APHON announces recipients of 2014 APHON Membership Awards

The Association of Pediatric Hematology/Oncology Nurses announced the recipients of the 2014 APHON Membership Awards at its 38th Annual Conference and Exhibit, held September 4-6 in Portland, OR. APHON Membership Awards recognize members who have shown outstanding achievement in their field.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Dr. Grace Campbell receives RNF Fellow Research Grant Award

The Rehabilitation Nursing Foundation (RNF) presents Dr. Grace Campbell, PhD BSN RN CRRN MSW, with the RNF Fellow Research Grant Award. RNF offers $30,000 in the form of multiple grants for research projects that address the clinical practice, educational or administrative dimensions of rehabilitation nursing. Dr. Campbell received her award at the ARN 40th Annual Educational Conference, October 29 - November 1, 2014 in Anaheim, CA.

5 Nov 2014

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Advaxis, Inc., a cancer immunotherapy company, today announced the abstracts of three preclinical and clinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

5 Nov 2014

Study suggests possible link between body fat and risk of immunotherapy toxicity

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found.

4 Nov 2014

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday).

4 Nov 2014

Study reveals impact of meditation, support groups at cellular level in breast cancer survivors

For the first time, researchers have shown that practising mindfulness meditation or being involved in a support group has a positive physical impact at the cellular level in breast cancer survivors.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

UC Davis researchers link increased body fat and lethal drug reactions in mice

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. The findings, published online today in The Journal of Experimental Medicine, suggest a possible link between body fat and the risk of toxicity from some types of immunotherapy.

3 Nov 2014

Eribulin drug could extend life of women with advanced triple negative breast cancer

THE cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Monday).

3 Nov 2014

Molecular profiling reveals potential therapeutic targets for lung cancer

Analysis of 607 small cell lung cancer (SCLC) lung tumors and neuroendocrine tumors (NET) identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

New DNA-based test could better predict treatment outcomes for prostate cancer patients

High-absorption BCM-95 Curcumin can reduce spread of cancer cells

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Prof. Dan Peer awarded grant for groundbreaking development in cancer treatment

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Researchers develop 'smart bomb' to attack B-lineage ALL

APHON announces recipients of 2014 APHON Membership Awards

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Dr. Grace Campbell receives RNF Fellow Research Grant Award

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Study suggests possible link between body fat and risk of immunotherapy toxicity

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Study reveals impact of meditation, support groups at cellular level in breast cancer survivors

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

UC Davis researchers link increased body fat and lethal drug reactions in mice

Eribulin drug could extend life of women with advanced triple negative breast cancer

Molecular profiling reveals potential therapeutic targets for lung cancer

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in